NeuroStim TMS Accomplishes Over 300,000 Treatment Sessions, Including One-Day TMS Milestone

NeuroStim TMS Reaches a Major Milestone in Mental Health Treatment

NeuroStim TMS, a prominent provider of Transcranial Magnetic Stimulation (TMS) Therapy, proudly announced a significant achievement—exceeding 300,000 TMS treatment sessions delivered across its network of 17 centers. This milestone also includes an impressive number of over 10,000 sessions utilizing the innovative One-Day TMS™ treatment protocol.

Since its establishment in early 2018, NeuroStim has been at the forefront of offering non-invasive and evidence-based therapeutic options for individuals struggling with various mental health issues, including depression, obsessive-compulsive disorder (OCD), and anxiety. The company has made it its mission to enhance mental health care accessibility and effectiveness through its advanced TMS services.

One-Day TMS™: A Game Changing Approach

One of the standout features of NeuroStim's offerings is the One-Day TMS™ treatment—a groundbreaking protocol that enables eligible patients to complete a full course of TMS in just a single day. This innovative approach originated from the results of the ONE-D clinical study, which NeuroStim developed and co-published, demonstrating the feasibility and safety of administering 20 TMS sessions within a 24-hour period. The study revealed remarkable response rates exceeding 90% and remission rates over 70% across various clinical assessments, showcasing the potential effectiveness of rapid TMS approaches.

Tasha Morris, MD, the Chief Medical Officer at NeuroStim TMS, expressed enthusiasm for the impact of accelerated therapies, stating, "Accelerated TMS has the potential to remove one of the greatest barriers to treatment—time. For many patients, completing treatment in a single day makes evidence-based therapy feasible when a traditional six-week schedule simply isn't an option."

Commitment to Innovation and Patient-Centric Care

With the ascent of demand for One-Day TMS™, NeuroStim is dedicated to expanding the reach of this treatment to suitable patients, providing a more efficient alternative to traditional antidepressant therapies. Walt Guidice, the CEO of NeuroStim TMS, highlighted the importance of the 300,000 treatment sessions milestone as a reflection of patient trust and acceptance of TMS therapy. He emphasized the company's commitment to quality care, innovation, and patient outcomes as they continue to expand their services.

Looking towards the future, NeuroStim plans not just to broaden its clinical footprint but also to ramp up investments in research and innovations that aim to make mental health care more accessible and effective nationwide.

About NeuroStim TMS

NeuroStim TMS stands out as a leading provider of Transcranial Magnetic Stimulation (TMS) Therapy, taking pride in being a research-active center committed to advancing neuromodulation science. Founded in 2018, the company boasts a team of specialists with backgrounds from prestigious institutions like Harvard, Columbia, and the Mayo Clinic. With 17 treatment centers across Washington, Arizona, and Minnesota, NeuroStim TMS focuses exclusively on delivering TMS therapy of the highest standard.

As they celebrate their achievements, NeuroStim remains steadfast in their mission to make evidence-based mental health treatments accessible to those in need, ensuring better outcomes for their patients while paving the way for further advancements in the field.